Rheumatism is a common chronic self-immunological disease, which, if not treated in a timely and effective manner, can lead to joint malformations and loss of function, seriously affecting the quality of life of patients. Here are some highlights of the treatment of rheumatitis:
I. Early diagnosis and intervention
Early diagnosis is key to improving the prognosis of rheumatism. Medical treatment should be provided in a timely manner in the event of symptoms such as joint pain, swelling, morning symmetry (especially multiple joint symmetry, long duration). An early and definitive diagnosis and initiation of treatment is carried out by improving the examination of rheumatist factors, anti-accumulant, blood sank, C-reacting proteins, etc., in conjunction with a joint visual examination (e.g. X-line, MRI imaging). Early treatment can effectively control inflammation and reduce joint damage.
II. Drug treatment
1. Inflammatory drugs (NSAIDs): This type of drug provides rapid relief for joint pain, swelling and other symptoms, such as Broven, dichlorphenic acid, etc. However, there is no control over the progress of the condition and long-term use is likely to have adverse gastrointestinal effects, which need to be selected and monitored on the basis of the individual circumstances of the patient.
2. DMARDs: The core drug for treatment should be used as early as possible. Methamidophos is the preferred option, including fluorometts, nitroglyphs, etc. They can slow down or prevent joint damage, but they work slowly and usually take weeks or months to be effective, with patient patience and regular monitoring of indicators such as blood protocol, liver and kidney function.
3. Biological agents: For patients with a high level of disease, a low level of reaction to traditional DMARDs or a pre-depressive factor, they may be considered for use. For example, tumour necrosis inhibitors (Inaseep, Innafliku, etc.), white medium – 6 inhibitors, etc. Biological agents are highly effective, but they are expensive and can increase the risk of infection, require rigorous pre-use screening to remove taboos and closely monitor adverse reactions during their use.
4. Sugar cortex hormones: has a strong anti-inflammatory effect and can rapidly improve symptoms. It is generally used for transitional treatment during a medical period, with small doses and short treatment to reduce adverse effects. For example, in the case of Ponesson, care is taken to prevent complications such as osteoporosis and infection.
Joint treatment
Single drugs are often difficult to fully control, and joint treatment programmes are common. For example, an association between DMARDs, or an association between DMARDs and biological agents. Joint treatment can improve the efficacy of treatment, reduce the dose of drugs and reduce the incidence of adverse effects, provided that individualized programmes are developed by doctors, taking into account the patient ‘ s medical, physical and financial circumstances.
Functional exercise and rehabilitation
During treatment, functional exercise cannot be ignored. Patients shall, as far as their condition permits, exercise in rehab, such as a degree of joint activity, muscle force training, such as simple actions such as handshakes, stretching fingers, stretching elbows and knee joints, with a gradual increase in activity intensity and scope. This helps to maintain joint functions, to prevent the convulsive deformities of the joints and to improve self-care.
Regular follow-up and monitoring
Patients are required to follow the hospital on a regular basis, once a month at the time of general initial treatment, with a gradual extension to three to six months after stable conditions. The follow-up visits included the assessment of joint symptoms, the detection of inflammatory indicators and the monitoring of adverse drug reactions. The doctor adjusts the treatment programme in a timely manner, based on the results of the follow-up visit, to ensure its effectiveness and safety.
In general, the treatment of rheumatism is a long-term, integrated process, requiring close collaboration between doctors and patients, and adherence to the principles of early, normative and individualized treatment, in order to achieve the goal of controlling the condition, reducing the disability rate and improving the quality of life.
